The Europe pharmaceutical glass packaging market is expected to grow significantly, increasing from about USD 5.79 billion in 2026 to nearly USD 12.39 billion by 2035, at a steady annual growth rate of around 8.8%. This growth is mainly driven by the rising use of biologic medicines and temperature-sensitive drugs that require reliable cold-chain storage. Across Europe, there is strong demand for high-quality borosilicate glass packaging because it helps prevent contamination, keeps medicines stable, and ensures they can be stored safely for long periods.
Recent Developments
- In January 2026, at Pharmapack Europe 2026, which was hosted in Paris between January 21-22, named as SUDPACK Medica, displayed its profile, which was crafted to solve sustainability and sterility needs, marked by the growth of the organization’s PharmaGuard recyclable blister idea and the launch of the MedHub service.
- In August 2025, SGD Pharma had revealed that it had entered into an official partnership with Entangled Capital, which is an Italian private equity firm, to gain Alphial, which is an Italy-based producer of ampoules and ready-to-use (RTU) glass products.
- In January 2025, DS Smith disclosed an inventive temperature-controlled packaging solution for the pharmaceutical sector, which is crafted to assist the sustainability goals of biotech and pharmaceutical organizations that align their demand to keep and transport sensitive medical products.
Top Companies in the Europe Pharmaceutical Glass Packaging Market
- Schott Pharma AG & Co. KGaA
- Gerresheimer AG
- Stevanato Group
- SGD Pharma
- Bormioli Pharma S.p.A.
- Ardagh Group S.A.
- Nipro Corporation
- Vetter Pharma
- O-I Glass, Inc.
- AptarGroup, Inc.
